Instillido

Lidocaine, the active ingredient in Instillido, is a local anesthetic presented as a sterile solution for urethral use. It provides a reversible blockade of nerve conduction, delivering rapid onset of numbness to facilitate diagnostic or therapeutic procedures involving the urethra, with a short duration suitable for outpatient settings.

GNH USA supplies Instillido as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and reliable global distribution.

Instillido (lidocaine) is used for urethral anesthesia, providing local pain relief during procedures affecting the urinary tract.

Urethral anesthesia for diagnostic procedures: enables painless cystoscopic examination. Urethral anesthesia for therapeutic procedures: facilitates interventions such as urethral dilation or stent placement. Urethral catheterization: reduces discomfort during catheter insertion.

Instillido may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Burning sensation at the application site - Mild itching or erythema - Transient dizziness

Serious or Rare Side Effects: - Allergic reaction including rash, swelling, or anaphylaxis - Cardiac arrhythmia or conduction disturbances - Seizures

When using Instillido, consider the following precautions to minimise risk.

Assess patient history for lidocaine allergy: avoid use in known hypersensitivity. Use the lowest effective volume: limit exposure to the urethral mucosa. Monitor cardiovascular status: be aware of potential arrhythmias in susceptible patients. Avoid concurrent use with other local anesthetics unless directed: may increase systemic toxicity. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Instillido can interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may potentiate cardiotoxicity. - CYP3A4 inhibitors (e.g., ketoconazole): can increase systemic lidocaine levels.

Moderate Interactions (Monitor Closely): - Class II antiarrhythmics (e.g., beta‑blockers): may enhance bradycardic effects. - Other local anesthetics: cumulative toxicity risk. - Epinephrine‑containing solutions: may alter absorption rate.